# Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes

> **NCT03580967** · PHASE4 · WITHDRAWN · sponsor: **Todd Doyle**

## Conditions studied

- Type2 Diabetes
- Major Depressive Disorder

## Interventions

- **DRUG:** Vortioxetine

## Key facts

- **NCT ID:** NCT03580967
- **Lead sponsor:** Todd Doyle
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-07-01
- **Primary completion:** 2021-07-01
- **Final completion:** 2021-07-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** COVID-19 Pandemic interfered with Pt recruitment
- **Last updated:** 2022-11-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03580967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03580967, "Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03580967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*